Jason C Brophy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1990542/publications.pdf

Version: 2024-02-01

567281 454955 44 920 15 30 g-index citations h-index papers 44 44 44 1456 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	A national review of vertical HIV transmission. Aids, 2012, 26, 757-763.	2.2	179
2	The Epidemiology, Management, and Outcomes of Bacterial Meningitis in Infants. Pediatrics, 2017, 140, .	2.1	127
3	Reducing the risk of pet-associated zoonotic infections. Cmaj, 2015, 187, 736-743.	2.0	84
4	Early Initiation of Combination Antiretroviral Therapy in HIV-1-Infected Newborns Can Achieve Sustained Virologic Suppression With Low Frequency of CD4+ T Cells Carrying HIV in Peripheral Blood. Clinical Infectious Diseases, 2014, 59, 1012-1019.	5.8	77
5	Longitudinal Outcomes in the 2014 Acute Flaccid Paralysis Cluster in Canada. Journal of Child Neurology, 2017, 32, 301-307.	1.4	50
6	Leukocyte Telomere Length in HIV-Infected and HIV-Exposed Uninfected Children: Shorter Telomeres with Uncontrolled HIV Viremia. PLoS ONE, 2012, 7, e39266.	2.5	47
7	The impact of electronic consultation on a Canadian tertiary care pediatric specialty referral system: A prospective single-center observational study. PLoS ONE, 2018, 13, e0190247.	2.5	36
8	HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine. Vaccine, 2016, 34, 4799-4806.	3.8	33
9	Identification of rare HIV-1–infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression. JCl Insight, 2019, 4, .	5.0	21
10	Prevention of Vertical HIV Transmission and Management of the HIV-Exposed Infant in Canada in 2014. Canadian Journal of Infectious Diseases and Medical Microbiology, 2014, 25, 75-77.	1.9	20
11	Clinical Correlates of Human Immunodeficiency Virus–1 (HIV-1) DNA and Inducible HIV-1 RNA Reservoirs in Peripheral Blood in Children With Perinatally Acquired HIV-1 Infection With Sustained Virologic Suppression for at Least 5 Years. Clinical Infectious Diseases, 2020, 70, 859-866.	5.8	20
12	Detailed Biochemical and Bioenergetic Characterization of FBXL4-Related Encephalomyopathic Mitochondrial DNA Depletion. JIMD Reports, 2015, 27, 1-9.	1.5	19
13	Safety of combination antiretroviral prophylaxis in highâ€risk HIVâ€exposed newborns: a retrospective review of the Canadian experience. Journal of the International AIDS Society, 2016, 19, 20520.	3.0	18
14	Missed opportunities for prevention of vertical HIV transmission in Canada, 1997–2016: a surveillance study. CMAJ Open, 2018, 6, E202-E210.	2.4	17
15	Knowledge, Attitudes, and Practices Related to Pet Contact by Immunocompromised Children with Cancer and Immunocompetent Children with Diabetes. Journal of Pediatrics, 2014, 165, 348-355.e2.	1.8	16
16	Adverse Neonatal Outcomes Among Women Living With HIV: A Population-Based Study. Journal of Obstetrics and Gynaecology Canada, 2015, 37, 302-309.	0.7	15
17	Blood Mitochondrial DNA Content in HIV-Exposed Uninfected Children with Autism Spectrum Disorder. Viruses, 2018, 10, 77.	3.3	15
18	Trends in live birth rates and adverse neonatal outcomes among HIV-positive women in Ontario, Canada, 2002–2009: a descriptive population-based study. International Journal of STD and AIDS, 2014, 25, 960-966.	1.1	10

#	Article	IF	CITATIONS
19	Immunogenicity and Safety of the Quadrivalent Human Papillomavirus Vaccine in Girls Living With HIV. Pediatric Infectious Disease Journal, 2018, 37, 595-597.	2.0	10
20	Elevated Blood Mitochondrial DNA in Early Life Among Uninfected Children Exposed to Human Immunodeficiency Virus and Combination Antiretroviral Therapy in utero. Journal of Infectious Diseases, 2021, 223, 621-631.	4.0	10
21	Adequacy of prenatal care among women living with human immunodeficiency virus: a population-based study. BMC Public Health, 2015, 15, 514.	2.9	9
22	Challenges to achieving and maintaining viral suppression among children living with HIV. Aids, 2020, 34, 687-697.	2.2	9
23	Association of outcomes in acute flaccid myelitis with identification of enterovirus at presentation: a Canadian, nationwide, longitudinal study. The Lancet Child and Adolescent Health, 2020, 4, 828-836.	5.6	9
24	Therapeutic drug Monitoring Guided Raltegravir Dosing for Prevention of Vertical Transmission in a Premature Neonate Born to a Woman Living with Perinatally Acquired HIV. Antiviral Therapy, 2017, 22, 545-549.	1.0	7
25	Brief Report: Higher Levels of Angiopoietin-1 Are Associated With Early and Sustained Viral Suppression in Children Living With Vertically Acquired HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 590-595.	2.1	7
26	Survival Outcomes in a Pediatric Antiretroviral Treatment Cohort in Southern Malawi. PLoS ONE, 2016, 11, e0165772.	2.5	7
27	Postpartum Maternal and Neonatal Hospitalizations Among Women with HIV: A Population-Based Study. AIDS Research and Human Retroviruses, 2015, 31, 967-972.	1.1	6
28	Enteroviral and herpes simplex virus central nervous system infections in infants < 90 days old: a Paediatric Investigators' Collaborative Network on Infections in Canada (PICNIC) study. BMC Pediatrics, 2020, 20, 252.	1.7	6
29	Leukocyte Telomere Length at Birth and During the Early Life of Children Exposed to but Uninfected With HIV After In Utero Exposure to Antiretrovirals. Journal of Infectious Diseases, 2018, 217, 710-720.	4.0	5
30	Artesunate Treatment of Severe Pediatric Malaria: A Review of Parasite Clearance Kinetics and Clinical Implications. Canadian Journal of Infectious Diseases and Medical Microbiology, 2015, 26, 237-240.	1.9	4
31	Predictive value of repeated cerebrospinal fluid parameters in the outcomes of bacterial meningitis in infants <90 days of age. PLoS ONE, 2020, 15, e0238056.	2.5	4
32	Inverse relationship between leukocyte telomere length attrition and blood mitochondrial DNA content loss over time. Aging, 2020, 12, 15196-15221.	3.1	4
33	Issues in Applying a Harm Reduction Approach to Breastfeeding in the Context of Maternal HIV. Clinical Infectious Diseases, 2015, 60, 672-674.	5.8	3
34	Impact of quadrivalent HPV vaccine dose spacing on immunologic response in women living with HIV. Vaccine, 2020, 38, 3073-3078.	3.8	3
35	Is â€~conflict of interest' a Misnomer? Managing interests in immunization research and evaluation. Human Vaccines and Immunotherapeutics, 2021, , 1-6.	3.3	3
36	Prescribing patterns of antiretroviral treatments during pregnancy for women living with <scp>HIV</scp> in Canada 2004–2020: A surveillance study. HIV Medicine, 2023, 24, 130-138.	2.2	3

#	Article	IF	CITATIONS
37	Assessing adolescent immunization options for pertussis in Canada: A cost-utility analysis. Vaccine, 2020, 38, 1825-1833.	3.8	2
38	Transition from Pediatric to Adult HIV Care for Young Women Living with HIV. Journal of the International Association of Providers of AIDS Care, 2020, 19, 232595822090357.	1.5	2
39	AMMI Canada: Response to FAQs about the management of children with congenital cytomegalovirus infection in Canada. Jammi, 2019, 4, 208-214.	0.5	2
40	British Columbia CARMA-CHIWOS Collaboration (BCC3): protocol for a community-collaborative cohort study examining healthy ageing with and for women living with HIV. BMJ Open, 2021, 11, e046558.	1.9	1
41	Paediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study of the Epidemiology of Bacterial and Fungal Meningitis in Infants Aged < 90 Days. Open Forum Infectious Diseases, 2016, 3, .	0.9	O
42	2342. Treatment Implications of Herpes Simplex Virus Central Nervous System Infection in Canadian Infants <90 Days Old: A Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) Study. Open Forum Infectious Diseases, 2018, 5, S696-S696.	0.9	0
43	44 Viral Central Nervous System Infections in Canadian Infants <90 Days Old: Encephalitis as a Predictor of Neurodevelopmental Morbidity. Paediatrics and Child Health, 2019, 24, e18-e18.	0.6	O
44	Factors associated with contraceptive use among women living with HIV in Canada: a controlled, cross-sectional study. Reproductive Health, 2022, 19, 3.	3.1	0